MOL #54254
Introduction iGluRs mediate the vast majority of excitatory neurotransmission in the mammalian brain and have been implicated in numerous CNS disorders (Bowie, 2008) . Given this, much effort has focused on their structure-function properties since, amongst other benefits, it provides a rational approach to drug discovery. Insight into their structure was first advanced by homology modeling using the bi-lobed domain of bacterial amino-acid binding proteins as a template (Stern-Bach et al., 1994) . Subsequently, the agonist-binding domain (ABD) of the GluA2 (Collingridge et al., 2009 ) (formerly GluR2 or GluRB) AMPAR was crystallized, revealing the predicted clamshell-like structure of globular domains 1 and 2 that close upon agonist binding (Armstrong and Gouaux, 2000) . Since then, a similar approach has permitted the atomic resolution of ABDs of all iGluR family members including the KAR (Nanao et al., 2005; Mayer, 2005) , NMDAR (Inanobe et al., 2005) and more recently, the delta-2 orphan iGluR (Naur et al., MOL #54254 5 domain closure elicited by the full agonist, L-Glu, differs from partial agonist, KA, by only 3 o (Mayer, 2005) which is modest in comparisons with the effect of the same agonists at AMPARs (e.g. L-Glu vs. KA, 8 o difference) (Armstrong and Gouaux, 2000) . An added complication is that the apo state of the KAR ABD has yet to be resolved; therefore, the extent of domain closure is given with respect to the GluA2 AMPAR apo state. Third and finally, KARs require external anions and cations as well as the neurotransmitter L-glutamate for activation (Wong et al., 2006 ); a property not shared by AMPARs (Bowie, 2002) . Given this, it is possible that the degree of activation of KARs is shaped not only by the agonist molecule but also external ions.
Here, we have tested the functionality of a range of L-Glu analogues as a first step in understanding the structural basis of agonist behavior at KARs. To complement this data, we also used the in silico ligand-docking program, FITTED, to predict the conformation of the ABD preferred by each agonist. Interestingly, this combined approach suggests unexpectedly that most partial agonists select for the closed and not the open or intermediate conformation of GluK2
ABD. This finding suggests that agonist efficacy at KARs may not be solely determined by the extent of closure in the GluK2 ABD and therefore, alternative structural models may need to be considered.

Materials and Methods
Cell Culture & Transfection. Techniques used to culture and transfect mammalian cells to express GluR6 KARs have been described in detail elsewhere (Bowie, 2002) . Briefly, tsA201
cells, a transformed human kidney (HEK 293) cell line stably expressing an SV40 temperature sensitive T antigen (provided by R. Horn, Jefferson Medical College, PA, USA) were maintained at a confluency of 70-80% in minimal essential medium with Earle's salts, 2 mM glutamine and 10% fetal bovine serum supplemented with penicillin (100 units per ml) and streptomycin (100 μ g per ml). After plating at low density (2 × 10 4 cells per ml) on plastic dishes, cells were transfected with cDNA encoding unedited rat glutamate receptor subunit 6 (GluR6Q) using the calcium phosphate technique as previously described (Bowie, 2002) . The cDNA for enhanced green fluorescent protein (EGFP S65T mutant) was routinely co-transfected to identify transfected cells. In this and all subsequent publications from our lab, we adopt the recommended change to iGluR nomenclature (Collingridge et al., 2009) . Consequently, GluR6
will be referred to as GluK2 and the GluR-B or GluR2 AMPAR subunit as GluA2.
Electrophysiological Solutions and Techniques. All ligands tested in this study were dissolved in external solutions containing 150 mM NaCl, 5 mM HEPES with low concentrations of CaCl 2 and MgCl 2 (0.1 mM each) to avoid divalent block. For dose-response relationships to D-and LAsp ( Fig. 3D) , however, agonists were applied at concentrations (i.e. > 100 mM) which would cause a shifting in reversal potential due to changes in the driving force for the main permeant ion, Na + . To avoid this, the ionic strength of all solutions was increased to 200 mM with the desired agonist concentration balanced by the appropriate amount of NaCl. All concentrated ligand solutions were adjusted to pH 7.3 with NaOH before being stored at -20 o C. Saturating
This article has not been copyedited and formatted. The final version may differ from this version. agonist concentrations chosen for L-Glu (10 mM), kainate (1 mM), domoate (50 μM) were at least 5-fold larger than published EC 50 values at GluK2 receptors. We confirmed empirically that these concentrations were saturating by doubling the agonist concentration in each case and observing that peak response amplitudes were unchanged. For sulfur-containing amino acids, QA, SYM 2081 as well as L-α-aminoadipate, saturating levels were determined empirically by increasing concentrations until a maximal response was observed. In cases where millimolar concentrations of agonist were required for activation (e.g. 40 mM L-cysteic acid), the reported response amplitudes were corrected for the shift in the reversal potential observed. Internal pipette solution contained 115 mM NaCl, 10 mM NaF, 5 mM HEPES, 5 mM Na 4 BAPTA, 0.5 mM CaCl 2 , 1 mM MgCl 2 and 10 mM Na 2 ATP to chelate endogenous polyamines. The pH and osmotic pressure of internal and external solutions were adjusted to 7.3 and 295 mOsm respectively. Concanavalin-A (Con-A) (Sigma, St. Louis) was prepared in glucose free saline solution and filtered (0.2 μm filter, Corning) immediately before use as described previously (Bowie et al., 2003) . All recordings were performed with an Axopatch 200B amplifier (Axon Instruments Inc., CA) using thin-walled borosilicate glass pipettes (2-5 MΩ) coated with dental wax to reduce electrical noise. Control and agonist solutions were rapidly applied to outside-out patches excised from transfected tsA201 cells as described previously (Bowie, 2002) . Solution exchange (10-90 % rise-time = 25-50 μs) was determined routinely at the end of the experiment by measuring the liquid junction current (or exchange current) between the control and agonistcontaining solution in which total Na + -content was reduced by 5%. Current records were filtered at 5 kHz, digitized at 25-50 kHz and series resistances (3-10 MΩ) compensated by 95 %. Most recordings were performed at -20 mV membrane potential to ensure adequate voltage clamp This article has not been copyedited and formatted. The final version may differ from this version. all these functions has recently been described (Corbeil et al., 2007) . This docking tool can uniquely accommodate for displaceable bridging water molecules while treating the ligand/protein as a realistically dynamic system and therefore provides the most appropriate docking approach to investigate iGluRs. For data shown in this study we used FITTED version 2.0 using the semi-flexible docking option with displaceable waters and, in each case, the pharmacophore-oriented docking function was used (Corbeil et al., 2007) .
Protein and ligand structure preparation prior to docking. The X-ray structures of GluK2 complexes were retrieved from the Protein Data Bank (PDB codes: 1s50, 1s7y, 1sd3, 1s9t, 1tt1, 1yae) and hydrogen atoms were added with their position optimized through energy MOL #54254 9 minimization. The result was visually inspected, as described previously to ensure the optimum hydrogen bond network (Corbeil et al., 2007) . Six bridging water molecules found to be conserved throughout most of the ligand-protein complexes were retained for the docking study.
All proteins structures were prepared using ProCESS (a module of FITTED) and the ligands were fully ionized and prepared with SMART (a module of FITTED) (Corbeil et al., 2007) .
Docking amino acid ligands using FITTED. The data obtained from docking experiments are summarized in Table 1 . Six protein structures initially resolved with five different agonists were used as input files (i.e. 1s7y (L-Glu), 1s9t (QA), 1sd3 (SYM 2081), 1tt1 (kainate), 1yae_a
(domoate, conformation 1) and 1yae_b (domoate, conformation 2). All the original PDB files pertain to KAR dimer structures solved with different ligands (Mayer, 2005) with the exception of 1yae which was solved as a hexamer (Nanao et al., 2005) . To compare GluK2 monomers within a given polymer, protein superimposition was achieved by aligning the alpha carbons of the residues found with at least one atom within 10 Å from the ligand. With the exception of 1yae, all the monomers within a given polymer were identical. Therefore, only one of the monomers per dimer was retained for the docking studies. As for 1yae, two monomers (1yae_a and 1yae_b) were retained as input files to allow for greater protein fluctuations within the binding pocket. The five agonists (L-Glu, QA, SYM 2081, KA and domoate) were docked using six protein structures as input files (1s7y, 1s9t, 1sd3, 1tt1, 1yae_a and 1yae_b Å). For the remainder of the text, the term "closed" conformation will be used to refer to any of these three protein conformations. In agreement with crystallographic studies (Nanao et al., 2005) , the "open" state will denote the conformation observed with domoate-bound crystals (RMSD between 1s7y and 1yae: 1.6 Å). Finally, the conformation adopted by the kainate-bound
GluR6 crystal conformation will be termed "intermediate" (RMSD between 1s7y and 1tt1: 0.91
We assessed the validity of FITTED 2.0 for GluK2 KARs in several ways. First, we performed statistical analysis comparing the ligand bound in the actual crystal structures with the docked ligand predicted by FITTED. A ligand pose was considered successfully docked when the RMSD relative to the ligand bound in the actual crystal structure was below 2.0 Å (Table 1 ) (Corbeil et al., 2007) . Second, the protein structure was considered to be accurately selected when the population favored that specific protein conformation over others (Corbeil et al., 2007) .
Thirdly, we compared the number and position of water molecules in the crystal structure with that predicted by FITTED. In all cases, FITTED correctly predicted the number and position of water molecules. For each pose, FITTED used the RankScore function to yield a docking score, an estimation of the free energy of binding including entropic contributions (Table 1) .
Importantly, although the scoring function has been trained to reproduce free energies of binding, the accuracy level is not high enough to make highly accurate predictions within two orders of magnitude in Ki. In addition, the apparent agonist affinity (see Fig. 3 ) is not governed only by the free energy of agonist binding but also by multiple aspects of ion-channel behavior that include channel gating properties and desensitization. A minimum set of 10 runs was carried out for each ligand (Corbeil et al., 2007) . An initial population of 500 was enough for docking of all GluK2 KAR ligands to reach the convergence criterion. Moreover, a maximum of 500 generations was used to reach convergence for each ligand.
This article has not been copyedited and formatted. The final version may differ from this version. Assumptions of molecular docking strategy. To perform molecular ligand docking experiments, four assumptions were made. Firstly, our modeling strategy pertained to transposing the information obtained from resolved crystal with the behavior of the mature receptor under physiological conditions. Our electrophysiological recordings from GluK2 KARs were performed under physiological pH (7.3-7.4), while most of the GluK2 S1S2 isolated cores were crystallized under conditions that were significantly more acidic (ranging from 4.0 to 6.5). To assess the effect (if any) of these pH fluctuations, we compared the two GluK2 KAR crystals in complex with L-Glu that were co-crystallized at distinct pH (1s50, pH = 8.0; 1s7y, pH = 4.8) (Mayer, 2005) . Visual inspection of the superimposed protein-ligand complexes revealed no significant differences between the two structures. We therefore used the 1s7y structure and did not further consider 1s50 in our analysis. Secondly, our modeling experiments assumed that all the amino acids tested bind in the same cavity between the S1S2 domains (i.e. the orthosteric site) as previously reported for other ligands co-crystallized with GluK2 KARs. Thirdly, since the apo state of GluK2 KARs has yet to be resolved, the degree of domain closure of the agonistbinding domain was obtained in comparison with the apo state of GluA2 AMPA receptor. and therefore their domain closure was considered indistinguishable in agreement with previous structural analysis (Mayer, 2005) .
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Results
L-Glu analogs exhibit a wide range of agonist activity at GluK2 receptors
In an effort to identify receptor ligands that exhibit the full range of agonist behavior, we studied the kinetic properties of a number of commercially available L-Glu analogs (see Methods) . In all cases, agonists were applied at saturating concentrations and at frequencies that permit full recovery from desensitization. Figure 1 shows the extended structure of the selected amino acids all of which possess a common L-Glu backbone. We purposely chose this group of amino acids since they would provide information on how agonist efficacy is shaped by changes in chain length, atom substitution, as well as the addition of side groups and/or sulfur groups.
Agonist activity of several of these amino acids have been previously reported at AMPARs, NMDARs and metabotropic glutamate receptors (Patneau and Mayer, 1990; Kingston et al., 1998), but not yet at KARs.
Almost all amino acids tested elicited membrane currents that consisted of a rapidly-rising peak response which declined in the presence of the agonist to a new equilibrium level ( Fig. 2 upper, Table 1 ). In some cases, as with L-serine-O-sulphate (SOS) and stereoisomers of serine (Ser) and aspartate (Asp), responses were difficult to resolve due to their small amplitude (even in high-expressing patches) which made detailed kinetic analysis problematic (Figs. 2 and 3).
Nevertheless, a wide range of agonist efficacy was observed amongst all the amino acids tested 
Desensitization does not profoundly affect estimates of peak response amplitude
Although solution exchanges performed in this study were rapid, relative rates of activation and desensitization may vary amongst different agonists. Consequently, agonists designated as poorly conducting (i.e. weak partial agonists) may, in fact, behave as full agonists if studied in the absence of desensitization. To address this issue, we looked more closely at SOS and the stereoisomers (i.e. D and L) of both Asp and Ser which were ideal for this purpose since these ligands represent the five weakest responding agonists which, as explained above, may reflect genuine partial agonist activity or result from rapid rates into desensitization. To delineate between these two possibilities, we examined agonist responses following treatment with the plant lectin, concanavalin-A (Con-A).
While Con-A does not block desensitization or shift apparent agonist affinity, it irreversibly increases current flow through GluK2 KARs (Bowie et al., 2003) . We reasoned that this property would permit better resolution of responses elicited by weakly responding agonists. Prior to Con-A treatment, typical responses elicited by each of these agonists were small in amplitude which made accurate analysis of their kinetic properties problematic as shown in figure 3A for 10 mM L-Asp and SOS. To allow comparison, membrane currents elicited by the full agonist, L-Glu (10 This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3A) . As anticipated, Con-A treatment (10 μM, 3-5 mins) increased current flow through GluK2 receptors activated by SOS and stereoisomers of both Asp and Ser making it possible to routinely study their peak responses (Fig. 3B) . From detailed analysis of the stereoisomers of Asp, two important characteristics of their response were revealed that unequivocally demonstrate that they behave as partial agonists.
First, stereoisomers of Asp elicited rapidly-rising, non-desensitizing membrane currents showing that these agonists are not weakly-responding due to the rapid onset of desensitization (Fig. 3B) .
Second, construction of activation curves for each agonist revealed that maximal responses in each case were significantly smaller than with L-Glu ( 
In silico ligand-docking correctly identifies conformations adopted by the GluK2 agonistbinding domain
To combine this functional data with in silico ligand-docking using FITTED, we first focused on receptor agonists previously co-crystallized with the isolated ligand binding core of GluK2 (Mayer, 2005; Nanao et al., 2005) . From electrophysiology recordings, we already identified kainate (1 mM KA) and domoate (50 μM Dom) as partial agonists at GluK2 receptors with Lglutamate (10 mM L-Glu), SYM 2081 (3 mM) and quisqualate (3 mM QA) all behaving as full agonists when applied at saturating concentrations ( Fig. 4A & B) . Peak KA and Dom responses This article has not been copyedited and formatted. The final version may differ from this version. were 39.1 ± 2.0 % (n = 10) and 15.3 ± 1.9 % (n = 8) respectively of the maximal full agonist response ( Figure 4B , (Mayer, 2005; Nanao et al., 2005) .
Consequently, our electrophysiological data supports the current view that agonist efficacy is determined by the degree of closure in the GluK2 ABD (Mayer, 2005; Nanao et al., 2005) .
To look at domain closure and binding mode, we performed in silico ligand-docking with the same series of receptor agonists using FITTED ( Fig. 4D -F ). FITTED is a suite of programs which is unique in that the fitting process permits flexibility in macromolecules (side chains and main chains) and the presence of bridging water molecules while treating protein/ligand complexes as realistic dynamic systems (Corbeil et al., 2007) . These characteristics are particularly relevant to the iGluR ABD since ligand and protein flexibility as well as water molecule mobility are critical determinants of agonist behavior (Arinaminpathy et al., 2006) . In practical terms, agonists were docked to previously published structures of GluK2 that together represent the closed, intermediate or open conformation of the ABD (see Methods for details). It is important to emphasize that the final structure only ever represents a composite of these input structures and that FITTED cannot predict a completely novel structure. Upon convergence of the fitting process, we were able to assign a preferred conformation of the GluK2 ABD to each agonist.
In agreement with published X-ray crystal structures (Mayer, 2005; Nanao et al., 2005) , the full agonist, L-Glu, selected the closed conformation (Fig. 4D) 
Agonist efficacy and predictions of domain closure do not correlate
We next broadened our analysis to include all L-Glu analogs. With the exception of KA and Dom, FITTED predicted that all amino acids bind preferentially to the closed conformation suggesting that agonist efficacy and the degree of closure in the GluK2 ABD are apparently not correlated (Fig. 5) . At first glance, this result was perplexing since it suggested that weak partial agonists, such as stereoisomers of Asp or Ser, elicit similar degrees of conformational change as L-Glu (Fig. 5B ). Our immediate concern was that the outcome of the modeling represented a local minimum in the fitting process that is nonsensical from a biological perspective. However, we excluded this on two counts. First, FITTED already predicted the correct docking orientation of ligands previously crystallized with the GluK2 ABD (c.f. Fig. 4) . Second, the binding mode of all other docked agonists was comparable to the binding orientation observed with L-Glu as would be expected. Typical binding orientation is illustrated by a visual inspection of the GluK2
This article has not been copyedited and formatted. The final version may differ from this version. ligand-binding pocket docked with L-α-aminoadipate (AA) and L-homocysteine sulfinic (CSA) (Fig. 5A) . In each case, the α -carboxyl groups of both partial agonists are predicted to form Hbonds with Ala518, Arg523 and AlaA689 (Fig. 5A) 
Domain closure is determined by ligand interaction with Tyrosine 488
If the degree of closure in the ABD is not correlated with agonist efficacy, what is the basis for differences in closure observed with some agonists? Visual inspection of the ligand-bound complexes predicted by FITTED reveals an important property of the GluK2 ABD unique to Dom-and KA-bound structures (Fig. 5C) . Specifically, the large side chain that extends from position 4 on the pyrrolidine ring of Dom causes a translational motion of Tyr488 which prevents complete closure of the GluK2 ABD. Likewise, the shorter side chain extending from the pyrrolidine ring of KA also causes steric hindrance but to a lesser extent accounting for the intermediate closure of the ABD. In contrast all other amino acids tested, including the full agonist, L-Glu, do not interact directly with Tyr488 and due to their compact structure allow complete closure of the agonist-binding pocket ( Figure 5B ). The exception to this is QA which possesses a bulky oxadiazolidine ring (Fig. 1) . In this case, however, the ring structure of QA occupies a different region of the GluK2 ABD from the pyrrolidine ring of Dom and KA.
Consequently, QA binds to GluK2 permitting complete closure of the ABD.
Conformational changes elicited by D-and L-Asp are indistinguishable from L-Glu
Although docking experiments with FITTED predicts that weak partial agonists, such as Dand L-Asp, bind to the closed conformation of the GluK2 ABD, it was nevertheless important to demonstrate this experimentally. To do this, we examined GluK2 responses following pretreatment with Con-A (Fig. 6) . Con-A binds to a number of N-glycosylated residues in and around the GluK2 ABD ). In the resting or apo state of the GluK2 ABD, access to these sites is unrestricted, as a result, Con-A can bind to the receptor. Con-A binding in turn leads to the upregulation of GluK2 responses as we have described previously (Bowie et al., 2003; Fay and Bowie, 2006) . A typical experiment showing this effect is illustrated in figure 6A .
Note that the equilibrium / peak response ratio to 10 mM L-Glu increased to 21.8 ± 2.9 % following pre-treatment with Con-A (10 μM, 3 mins) ( Fig. 6A & C) . Conversely, if appreciable conformational changes are induced in the GluK2 ABD, such as occurs following L-Glu binding , Con-A's access to its binding sites are significantly restricted. As a consequence, pre-treatment with Con-A has only a modest effect on the GluK2 response. In the example shown in figure 6A , the equilibrium / peak response ratio to L-Glu observed following pre-treatment with Con-A was increased only to 6.7 ±1.8 % (Fig. 6A & C) .
State-dependent modulation by Con-A was therefore used to report the conformational changes elicited by D-and L-Asp. As positive controls, we compared the amount of modulation observed when GluK2 receptors were pre-incubated with Con-A and one of 3 agonists (i.e. 10 mM L-Glu, 1 mM KA or 50 μM Dom) ( Fig. 6A and C) . We have shown previously that Con-A modulation of GluK2 receptors pre-incubated with Glu, KA or Dom corresponds to the closed, intermediate or open states of the ABD respectively (Fig. 6C) . As negative controls, we examined pharmacological compounds that would not be expected to induce significant closure of the GluK2 ABD which were the competitive antagonist, 6-Cyano-7-This article has not been copyedited and formatted. The final version may differ from this version. nitroquinoxaline-2,3-dione (CNQX), as well as the ion-channel blocker, philanthotoxin (PhTX).
Although CNQX induces modest closure in the AMPAR ABD by acting as a partial agonist (Menuz et al., 2007) , this effect has not been observed at KARs consequently, we have assumed it behaves as a competitive antagonist.
As expected, pre-incubation with CNQX or PhTX did not interfere with the degree of modulation of GluK2 receptors by Con-A (Fig. 6B & C) . In support of this, the degree of Con-A modulation observed with CNQX or PhTX was similar to that observed for the open conformation of the GluK2 ABD but statistically distinct from the closed or intermediate (Table   2 ). These findings suggest that occupancy of the pore with a channel blocker or the ABD with a competitive antagonist does not evoke appreciable closure of the GluK2 ABD. In contrast, preincubation with either D-or L-Asp significantly reduced the degree of Con-A modulation ( 
Can other mechanisms account for agonist efficacy at kainate receptors?
Although the view that agonist efficacy is governed by closure in the ABD has gained much popularity, recent work on AMPARs has identified a different mechanism (though not mutually exclusive) (Robert et al., 2005; Zhang et al., 2008) that may also account for full and partial agonist behavior at KARs. In essence, it is argued that the time the ABD remains in the closed conformation determines several gating properties of AMPARs including agonist efficacy, deactivation rates as well as apparent agonist affinity. For L-Glu, closed-cleft stability is optimized by direct and indirect interactions with domains 1 and 2 of the AMPAR ABD which permit L-Glu to attain full agonist activity whilst exhibiting rapid unbinding (Robert et al., This article has not been copyedited and formatted. The final version may differ from this version. Zhang et al., 2008) ; essential features for any fast-acting neurotransmitter. In the specific case of AMPARs, mutation of a key threonine (i.e. Thr686) residue in domain 2 of the GluR2 ABD, disrupts the optimization established between the ligand and receptor. As a result, L-Glu is rendered a weak partial agonist with much lower affinity (Robert et al., 2005) .
There are several reasons to suggest that basic elements of the mechanism proposed by Zhang et al (2008) may also account for differences in efficacy between L-Glu and stereoisomers of Asp reported in this study. First, activation curves of partial agonists, D-and L-Asp, are rightward shifted compared to the full agonist, L-Glu ( Fig. 3C and D) , suggesting that, in this case, agonist efficacy and affinity may be tightly correlated. Second, deactivation rates for stereoisomers of Asp (e.g. D-Asp, τ = 1.2 ± 0.3 ms) were faster than with L-Glu (τ = 2.6 ± 0.2 ms) (Bowie, 2002) . Third and finally, the more extended structure of L-Glu permits more contact points (direct and indirect) to be established with the GluK2 ABD than with D-or L-Asp (Fig.   7 ). This difference in agonist binding would be expected to weaken the stability of the closed GluK2 ABD. Notably, L-Asp formed considerably less contacts than D-Asp or L-Glu which may explain its weaker responsiveness based on analysis of activation curves (Fig. 3D) . Although more work is required to rigorously test this model, it provides a valuable framework for future work on agonist behavior at KARs.
Are amino acids other than L-Glu suitable neurotransmitter candidates at kainate receptors?
Several of the amino acids examined in this study are endogenous to the CNS and have been previously evaluated as neurotransmitter candidates at glutamatergic synapses. The candidature of sulfur-containing amino acids, which include L-Cys, HC, SSC and HCSA, was considered after mechanisms that lead to their release, uptake and responsiveness (see below) were This article has not been copyedited and formatted. The final version may differ from this version. identified (Do et al., 1986; Bouvier et al., 1991) . Recent attention has focused on their potent activation of metabotropic glutamate receptors (e.g. (Kingston et al., 1998) ). However, earlier work demonstrated that they also activate iGluRs (Thompson and Kilpatrick, 1996) . At the time, most investigators argued for their greater ability to activate NMDARs than AMPARs (Patneau and Mayer, 1990) however, their effect on KARs was never tested. The reason being that evidence for the existence of this iGluR subclass had yet to emerge (Bowie, 2008) . In view of this, our data on homomeric GluK2 receptors suggests the value in testing the responsiveness of native KARs to sulfur-containing amino acids. Interestingly, the most potent sulfur-containing amino acid in our experiments, L-Cys, is a very weak partial agonist on homomeric GluR1
AMPARs (Fay and Bowie, unpublished observation) . Therefore it would be interesting in future work to determine if different non-NMDA receptor subtypes discriminate amongst sulfurcontaining amino acids.
In comparison, there is more compelling evidence linking the stereoisomers of both serine and aspartate to roles in glutamatergic transmission (Boehning and Snyder, 2003) . D-Ser was considered in this capacity only after it was shown to act as a co-agonist at the glycine binding site of NMDARs (McBain et al., 1989) . Since D-serine is expressed in discrete populations of glial cells opposed to NMDARs (Schell et al., 1997a) , it has been categorized as a gliotransmitter (Mothet et al., 2000; Panatier et al., 2006) . The role of D-Asp is more elusive although it is found in the developing and adult brain (Schell et al., 1997b) . Accumulation of D-Asp in CNS tissue has marked behavioral consequences, such as impaired motor coordination (Weil et al., 2006) , which is consistent with its putative role as a transmitter at the climbing fibers of the cerebellum (Wiklund et al., 1982) . Similarly, L-Asp's role in neurotransmission has centered on NMDARs (Fleck et al., 1993) , although, it elicits a high calcium conductance in cerebellar Purkinje cells that apparently involves a novel iGluR (Yuzaki et al., 1996) . Our study shows that D-and LThis article has not been copyedited and formatted. The final version may differ from this version. forms of each amino acid are weak partial agonists and, although these properties are not normally expected of a neurotransmitter candidate, it may be interesting to evaluate their roles at native KAR-containing synapses.
Conclusion
It is puzzling that not all iGluR subunits respond to the neurotransmitter, L-Glu. In fact, neither the NR1 NMDAR subunit nor the orphan-class delta-2 (δ2) subunit even bind L-Glu.
Since the ancestral iGluR, GluR0, possesses a L-Glu binding pocket (Chen et al., 1999) , it is conceivable that evolving NR1 and δ 2 subunits sacrificed this ability in order to serve more specialized roles in the mammalian CNS. In this regard, it is interesting that NMDARs (McBain et al., 1989) and orphan-class This article has not been copyedited and formatted. The final version may differ from this version. Interestingly, KA has the same effect though to a lesser extent due to its smaller side-chain that extends from the pyrrolidine ring. Agonists, water molecules and selected key residues are shown as sticks. Non-polar hydrogens have been omitted for clarity.
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